Pallavi Bommareddy of our Summer 2024 internship class has unfortunately wrapped up her term with us this past week, although she offered a very engaging and astute presentation on her way out concerning the pharmaceutical supply chain and COVID-19. She began with a comprehensive but concise outline of the pharmaceutical supply chain, including manufacturing of active ingredients, packaging, wholesale, distribution, and so on, which set up exactly how these components broke down during the COVID-19 pandemic; namely, concentration of active ingredients manufacturing in India & China, shipping delays, and regulatory challenges. In her review of the federal government’s response, Pallavi discovered that most efforts center around white papers and supply chain transparency at the manufacturer level, rather than genuine efforts to deconsolidate and localize supply chains to avoid future disruptions.